| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5883019 | Clinical Lymphoma Myeloma and Leukemia | 2013 | 5 Pages |
Abstract
MRD is still detectable using clonogenic assays in some patients with CML after achieving CMR using TKI therapy, which is likely responsible for relapse on TKI discontinuation. Because of the large number of single colonies that need to be analyzed, the use of clonogenic assays in clinical practice to determine the feasibility of TKI discontinuation is not recommended.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Alfonso Quintás-Cardama, Srdana Grgurevic, Uri Rozovski, Ping Li, Zeev Estrov, Jorge Cortes,